Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class ASSE: 603707

"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on Change in Accounting Policies

Aug 28, 2026 · Issued by Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on Change in Accounting Policies

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A

"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on the U.S. FDA Approval of the Subsidiary's Insulin Aspart InjectionJul 28
"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on Obtaining the Drug Registration Approval for Propofol Emulsion Injection by the National Medical Products AdministrationJul 7
"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd."Announcement on the Subsidiary's Receipt of the U.S. FDA Approval for the Manufacturing Site Transfer Registration of Desmopressin Acetate InjectionJul 4
Announcement on Implementation of Dividend Distribution for 2025Jun 3

All Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A news releases